Earnings ·
Kardigan, Inc. reported financial results for the fiscal quarter ended June 30, 2026, posting a net loss of $116.2…
KARDKardigan, Inc.
Kardigan, Inc. reported financial results for the fiscal quarter ended June 30, 2026, posting a net loss of $116.2 million compared to $57.4 million in the prior year period. Research and development expenses increased to $56.4 million from $35.8 million due to clinical trial costs and headcount growth, while general and administrative expenses decreased to $18.9 million from $21.3 million. The company ended the quarter with a cash position of $660.7 million, supported by $460 million in gross proceeds from its initial public offering completed in June 2026. Clinically, Phase 3 enrollment for danicamtiv (KINSHIP-DCM) is underway, and the first patient was randomized in the tonlamarsen (KARDINAL-ASH) Phase 2 trial. Kardigan operates as a clinical-stage precision therapeutics company developing medicines targeting cardiovascular diseases with no approved treatments.